These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 7838312)

  • 1. Potential parkinsonian protoxicants within and without.
    Collins MA
    Neurobiol Aging; 1994; 15(2):277-8. PubMed ID: 7838312
    [No Abstract]   [Full Text] [Related]  

  • 2. MPTP and other Parkinson-inducing agents.
    Schapira AH
    Curr Opin Neurol Neurosurg; 1992 Jun; 5(3):396-400. PubMed ID: 1623269
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Endogenous dopamine-derived neurotoxins and Parkinson's disease.
    Deleu D
    Acta Neurol Belg; 1998 Dec; 98(4):319-21. PubMed ID: 9922818
    [No Abstract]   [Full Text] [Related]  

  • 4. MPTP-induced neurotoxicity and the quest for a preventative therapy for Parkinson's disease.
    Furtado JC; Mazurek MF
    Can J Neurol Sci; 1991 Feb; 18(1):77-82. PubMed ID: 2036621
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Astrocytes and Parkinson's disease.
    Forno LS; DeLanney LE; Irwin I; Di Monte D; Langston JW
    Prog Brain Res; 1992; 94():429-36. PubMed ID: 1287728
    [No Abstract]   [Full Text] [Related]  

  • 6. MPTP-induced parkinsonism.
    Stern Y
    Prog Neurobiol; 1990; 34(2):107-14. PubMed ID: 2181530
    [No Abstract]   [Full Text] [Related]  

  • 7. [Sleep disorders and impaired learning ability in rats with parkinsonian syndrome induced by MPTP].
    Nerobkova LN; Markina NV; Voronina TA; Kraĭneva VA; Garibova TL; Molodavkin GM; Sharkova LM
    Biull Eksp Biol Med; 1996 Sep; 122(9):288-91. PubMed ID: 8974482
    [No Abstract]   [Full Text] [Related]  

  • 8. The MPTP-lesioned non-human primate models of Parkinson's disease. Past, present, and future.
    Fox SH; Brotchie JM
    Prog Brain Res; 2010; 184():133-57. PubMed ID: 20887873
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Might environmental factors contribute to neurodegenerative diseases?
    Tipton KF
    Biochem Soc Trans; 1995 May; 23(2):429-35. PubMed ID: 7672436
    [No Abstract]   [Full Text] [Related]  

  • 10. Gangliosides and parkinsonism.
    Herrero MT; Kastner A; Perez-Otaño I; Hirsch EC; Luquin MR; Javoy-Agid F; Del Río J; Obeso JA; Agid Y
    Neurology; 1993 Oct; 43(10):2132-4. PubMed ID: 8413979
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Excitatory amino acids and MPTP toxicity.
    Fornai F; Vaglini F; Maggio R; Bonuccelli U; Corsini GU
    Adv Neurol; 1996; 69():167-76. PubMed ID: 8615126
    [No Abstract]   [Full Text] [Related]  

  • 12. The neurotoxicity of MPTP and the relevance to Parkinson's disease.
    McCrodden JM; Tipton KF; Sullivan JP
    Pharmacol Toxicol; 1990 Jul; 67(1):8-13. PubMed ID: 2204050
    [No Abstract]   [Full Text] [Related]  

  • 13. [MPTP: a new chapter in the history of Parkinson's disease].
    Piccinin GL; Piccirilli M; Finali G; Stefano E
    Riv Neurol; 1989; 59(3):103-7. PubMed ID: 2688042
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Progression and recovery of Parkinsonism in a chronic progressive MPTP-induction model in the marmoset without persistent molecular and cellular damage.
    Franke SK; van Kesteren RE; Wubben JA; Hofman S; Paliukhovich I; van der Schors RC; van Nierop P; Smit AB; Philippens IH
    Neuroscience; 2016 Jan; 312():247-59. PubMed ID: 26431624
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MRI detects acute degeneration of the nigrostriatal dopamine system after MPTP exposure in hemiparkinsonian monkeys.
    Miletich RS; Bankiewicz KS; Quarantelli M; Plunkett RJ; Frank J; Kopin IJ; Di Chiro G
    Ann Neurol; 1994 Jun; 35(6):689-97. PubMed ID: 8210225
    [TBL] [Abstract][Full Text] [Related]  

  • 16. N-methyl-(R)-salsolinol and Parkinson's disease.
    Perrine DM
    Lancet; 1998 Jun; 351(9118):1818. PubMed ID: 9635986
    [No Abstract]   [Full Text] [Related]  

  • 17. Differential effect of chronic dopaminergic treatment on dopamine D1 and D2 receptors in the monkey brain in MPTP-induced parkinsonism.
    Graham WC; Sambrook MA; Crossman AR
    Brain Res; 1993 Feb; 602(2):290-303. PubMed ID: 8095431
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Changes of tyrosine hydroxylase in parkinsonian brains and in the brains of MPTP-treated mice.
    Nagatsu T
    Adv Neurol; 1990; 53():207-14. PubMed ID: 1978515
    [No Abstract]   [Full Text] [Related]  

  • 19. [A new model of depressive syndrome in rats caused by administering 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)].
    Kryzhanovskiĭ GN; Krupina NA; Kucherianu VG
    Biull Eksp Biol Med; 1995 Feb; 119(2):125-8. PubMed ID: 7670030
    [No Abstract]   [Full Text] [Related]  

  • 20. Stable parkinsonian syndrome and uneven loss of striatal dopamine fibres following chronic MPTP administration in baboons.
    Hantraye P; Varastet M; Peschanski M; Riche D; Cesaro P; Willer JC; Maziere M
    Neuroscience; 1993 Mar; 53(1):169-78. PubMed ID: 8469305
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.